Switch to:
Also traded in: Austria, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt 1.81
REGN's Cash-to-Debt is ranked lower than
73% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. REGN: 1.81 )
Ranked among companies with meaningful Cash-to-Debt only.
REGN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.57  Med: 2.08 Max: No Debt
Current: 1.81
Equity-to-Asset 0.68
REGN's Equity-to-Asset is ranked lower than
56% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. REGN: 0.68 )
Ranked among companies with meaningful Equity-to-Asset only.
REGN' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.18  Med: 0.65 Max: 0.95
Current: 0.68
0.18
0.95
Interest Coverage 102.35
REGN's Interest Coverage is ranked lower than
74% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. REGN: 102.35 )
Ranked among companies with meaningful Interest Coverage only.
REGN' s Interest Coverage Range Over the Past 10 Years
Min: 10.1  Med: 22.05 Max: 184.95
Current: 102.35
10.1
184.95
Piotroski F-Score: 7
Altman Z-Score: 13.80
Beneish M-Score: -2.66
WACC vs ROIC
12.41%
29.38%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 32.29
REGN's Operating Margin % is ranked higher than
92% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. REGN: 32.29 )
Ranked among companies with meaningful Operating Margin % only.
REGN' s Operating Margin % Range Over the Past 10 Years
Min: -91.55  Med: 3.92 Max: 35.3
Current: 32.29
-91.55
35.3
Net Margin % 22.05
REGN's Net Margin % is ranked higher than
88% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. REGN: 22.05 )
Ranked among companies with meaningful Net Margin % only.
REGN' s Net Margin % Range Over the Past 10 Years
Min: -84.46  Med: -2.95 Max: 54.43
Current: 22.05
-84.46
54.43
ROE % 24.67
REGN's ROE % is ranked higher than
94% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. REGN: 24.67 )
Ranked among companies with meaningful ROE % only.
REGN' s ROE % Range Over the Past 10 Years
Min: -43.76  Med: -0.78 Max: 86.68
Current: 24.67
-43.76
86.68
ROA % 16.07
REGN's ROA % is ranked higher than
94% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. REGN: 16.07 )
Ranked among companies with meaningful ROA % only.
REGN' s ROA % Range Over the Past 10 Years
Min: -18.38  Med: 0.35 Max: 44.08
Current: 16.07
-18.38
44.08
ROC (Joel Greenblatt) % 52.45
REGN's ROC (Joel Greenblatt) % is ranked higher than
90% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. REGN: 52.45 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
REGN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -173.81  Med: 7.5 Max: 61.97
Current: 52.45
-173.81
61.97
3-Year Revenue Growth Rate 30.20
REGN's 3-Year Revenue Growth Rate is ranked higher than
80% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. REGN: 30.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
REGN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -25  Med: 24.1 Max: 81.1
Current: 30.2
-25
81.1
3-Year EBITDA Growth Rate 20.70
REGN's 3-Year EBITDA Growth Rate is ranked higher than
73% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. REGN: 20.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
REGN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -56.7  Med: 22.7 Max: 122.8
Current: 20.7
-56.7
122.8
3-Year EPS without NRI Growth Rate 27.40
REGN's 3-Year EPS without NRI Growth Rate is ranked higher than
80% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. REGN: 27.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
REGN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -38.3  Med: -5.8 Max: 86.3
Current: 27.4
-38.3
86.3
GuruFocus has detected 5 Warning Signs with Regeneron Pharmaceuticals Inc $REGN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» REGN's 30-Y Financials

Financials (Next Earnings Date: 2017-11-04 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

REGN Guru Trades in Q3 2016

George Soros 1,381 sh (New)
Paul Tudor Jones 4,608 sh (+55.89%)
Ken Fisher 620 sh (+1.14%)
Vanguard Health Care Fund 3,279,190 sh (unchged)
Jim Simons Sold Out
Ron Baron 4,924 sh (-1.26%)
Frank Sands 2,497,378 sh (-6.10%)
Joel Greenblatt 24,745 sh (-17.93%)
Mario Gabelli 529 sh (-60.20%)
Eaton Vance Worldwide Health Sciences Fund 60,662 sh (-43.94%)
» More
Q4 2016

REGN Guru Trades in Q4 2016

Jim Simons 250,560 sh (New)
Manning & Napier Advisors, Inc 440,316 sh (New)
Ken Fisher 715 sh (+15.32%)
Vanguard Health Care Fund 3,309,690 sh (+0.93%)
Ron Baron 4,969 sh (+0.91%)
Eaton Vance Worldwide Health Sciences Fund 60,662 sh (unchged)
Mario Gabelli Sold Out
George Soros Sold Out
Paul Tudor Jones Sold Out
Frank Sands 2,302,802 sh (-7.79%)
Joel Greenblatt 12,096 sh (-51.12%)
» More
Q1 2017

REGN Guru Trades in Q1 2017

Steven Cohen 70,000 sh (New)
Paul Tudor Jones 600 sh (New)
Ron Baron 6,429 sh (+29.38%)
Frank Sands 2,933,444 sh (+27.39%)
Ken Fisher 806 sh (+12.73%)
Vanguard Health Care Fund 3,635,985 sh (+9.86%)
Joel Greenblatt Sold Out
Jim Simons 232,076 sh (-7.38%)
Manning & Napier Advisors, Inc 376,003 sh (-14.61%)
Eaton Vance Worldwide Health Sciences Fund 45,415 sh (-25.13%)
» More
Q2 2017

REGN Guru Trades in Q2 2017

Mario Gabelli 492 sh (New)
Ken Fisher 1,411 sh (+75.06%)
Ron Baron 7,061 sh (+9.83%)
Jim Simons Sold Out
Paul Tudor Jones Sold Out
Steven Cohen Sold Out
Frank Sands 2,793,959 sh (-4.75%)
Vanguard Health Care Fund 3,255,810 sh (-10.46%)
Manning & Napier Advisors, Inc 298,778 sh (-20.54%)
Eaton Vance Worldwide Health Sciences Fund 39,536 sh (-12.95%)
» More
» Details

Insider Trades

Latest Guru Trades with REGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2017-06-30 Reduce -10.46%0.33%$366.06 - $526.53 $ 467.987%3,255,810
Ron Baron 2017-06-30 Add 9.83%$366.06 - $526.53 $ 467.987%7,061
Ken Fisher 2017-06-30 Add 75.06%$366.06 - $526.53 $ 467.987%1,411
Mario Gabelli 2017-06-30 New Buy$366.06 - $526.53 $ 467.987%492
Vanguard Health Care Fund 2017-03-31 Add 9.86%0.28%$340.75 - $397.8 $ 467.9826%3,635,985
Ron Baron 2017-03-31 Add 29.38%$340.75 - $397.8 $ 467.9826%6,429
Ken Fisher 2017-03-31 Add 12.73%$340.75 - $397.8 $ 467.9826%806
Joel Greenblatt 2017-03-31 Sold Out 0.06%$340.75 - $397.8 $ 467.9826%0
Vanguard Health Care Fund 2016-12-31 Add 0.93%0.03%$336.01 - $444.52 $ 467.9823%3,309,690
Joel Greenblatt 2016-12-31 Reduce -51.12%0.07%$336.01 - $444.52 $ 467.9823%12,096
Ron Baron 2016-12-31 Add 0.91%$336.01 - $444.52 $ 467.9823%4,969
Ken Fisher 2016-12-31 Add 15.32%$336.01 - $444.52 $ 467.9823%715
George Soros 2016-12-31 Sold Out 0.02%$336.01 - $444.52 $ 467.9823%0
Mario Gabelli 2016-12-31 Sold Out $336.01 - $444.52 $ 467.9823%0
Joel Greenblatt 2016-09-30 Reduce -17.93%0.02%$358.5 - $441.37 $ 467.9817%24,745
Ron Baron 2016-09-30 Reduce -1.26%$358.5 - $441.37 $ 467.9817%4,924
George Soros 2016-09-30 New Buy0.02%$358.5 - $441.37 $ 467.9817%1,381
Ken Fisher 2016-09-30 Add 1.14%$358.5 - $441.37 $ 467.9817%620
Mario Gabelli 2016-09-30 Reduce -60.20%$358.5 - $441.37 $ 467.9817%529
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:BIIB, NAS:VRTX, NAS:ALXN, NAS:INCY, NAS:BMRN, NAS:EXEL, NAS:ALNY, NAS:KITE, NAS:SGEN, NAS:BIVV, NAS:TSRO, NAS:IONS, NAS:UTHR, NAS:GILD, NAS:NBIX, NAS:TECH, NAS:BLUE, NAS:ACAD, NAS:CLVS, NAS:PTLA » details
Traded in other countries:REGN.Austria, RGO.Germany, REGN.Mexico, REGN.Switzerland, 0R2M.UK,
Headquarter Location:USA
Regeneron Pharmaceuticals Inc is an integrated biopharmaceutical company. It discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has five marketed products: Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Zaltrap in colorectal cancer; Dupixent in atopic dermatitis; and Arcalyst in CAPS. Regeneron is also developing monoclonal antibodies with Sanofi in rheumatoid arthritis, asthma, and cancer.

Guru Investment Theses on Regeneron Pharmaceuticals Inc

Baron Funds Comments on Regeneron Pharmaceuticals - May 23, 2016

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) fell in the first quarter as a result of the significant sell-off in the biotech/pharma space and a miss on the top and bottom lines versus the expected fourth quarter results. 2016 guidance for Eylea (its lead ophthalmology asset) was sharply down from 2015. Launch of its new cardiovascular drug, Praluent, has been slow, and it lost a court case involving the drug. We have trimmed our position but decided that Regeneron deserved benefit of the doubt. Given Sanofi’s 22% ownership and its reliance on company for R&D productivity, we believe Regeneron enjoys a privileged position in the biotech universe.



From Baron Fifth Avenue Growth Fund first quarter commentary 2016.



Check out Ron Baron latest stock trades

Top Ranked Articles about Regeneron Pharmaceuticals Inc

Vanguard Sells Medtronic, Cigna in 2nd Quarter Largest sales of the most recent quarter
Vanguard Health Care Fund (Trades, Portfolio) owns a portfolio composed of 74 stocks with a total value of $46.532 billion. During the second quarter the guru sold shares in the following stocks: Read more...
Regeneron to Discontinue Development of Suptavumab for Respiratory Syncytial Virus
Options Trades for Allergan, 3D Systems, Regeneron Pharmaceuticals, Tesla Motors and Yelp include trade ideas that offer returns of 26% or more!
Accessing the Regeneron Second Quarter 2017 Financial and Operating Results Webcast
Regeneron and Sanofi Receive Positive CHMP Opinion for Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis
The Best- and Worst-Performing Stocks of the Last Decade The list and observations
In a recent article I shared a list of the 30 best-performing stocks since 1980. One of the readers was kind enough to leave a comment and suggested that I should run the lists of different time periods and compare them to see which companies consistently show up on the list. Read more...
Regeneron to Report Second Quarter 2017 Financial and Operating Results and Host Conference Call and Webcast on August 3, 2017
Regeneron Announces the 2017 Winners of the Regeneron Prize for Creative Innovation
Spiros Segalas Gains 5 New Holdings in 2nd Quarter Guru invests in technology and pharmaceutical companies
Spiros Segalas (Trades, Portfolio)’ Harbor Capital Appreciation Fund gained five new holdings in the second quarter. They are Activision Blizzard Inc. (NASDAQ:ATVI), Crown Castle International Corp. (NYSE:CCI), Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) and Snap Inc. (NYSE:SNAP). Read more...
Regeneron Details Royalty Agreement with Novartis for Canakinumab (ACZ885)

Ratios

vs
industry
vs
history
PE Ratio 46.99
REGN's PE Ratio is ranked lower than
76% of the 235 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. REGN: 46.99 )
Ranked among companies with meaningful PE Ratio only.
REGN' s PE Ratio Range Over the Past 10 Years
Min: 22.84  Med: 68.79 Max: 169.6
Current: 46.99
22.84
169.6
Forward PE Ratio 32.36
REGN's Forward PE Ratio is ranked lower than
81% of the 62 Companies
in the Global Biotechnology industry.

( Industry Median: 21.98 vs. REGN: 32.36 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 46.99
REGN's PE Ratio without NRI is ranked lower than
75% of the 236 Companies
in the Global Biotechnology industry.

( Industry Median: 31.31 vs. REGN: 46.99 )
Ranked among companies with meaningful PE Ratio without NRI only.
REGN' s PE Ratio without NRI Range Over the Past 10 Years
Min: 22.84  Med: 68.79 Max: 169.6
Current: 46.99
22.84
169.6
Price-to-Owner-Earnings 124.93
REGN's Price-to-Owner-Earnings is ranked lower than
67% of the 139 Companies
in the Global Biotechnology industry.

( Industry Median: 34.46 vs. REGN: 124.93 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
REGN' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 47.71  Med: 103.75 Max: 1511.41
Current: 124.93
47.71
1511.41
PB Ratio 9.08
REGN's PB Ratio is ranked lower than
84% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. REGN: 9.08 )
Ranked among companies with meaningful PB Ratio only.
REGN' s PB Ratio Range Over the Past 10 Years
Min: 2.47  Med: 9.87 Max: 26.41
Current: 9.08
2.47
26.41
PS Ratio 10.36
REGN's PS Ratio is ranked higher than
52% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. REGN: 10.36 )
Ranked among companies with meaningful PS Ratio only.
REGN' s PS Ratio Range Over the Past 10 Years
Min: 3.69  Med: 12.34 Max: 28.22
Current: 10.36
3.69
28.22
Price-to-Free-Cash-Flow 55.36
REGN's Price-to-Free-Cash-Flow is ranked lower than
66% of the 125 Companies
in the Global Biotechnology industry.

( Industry Median: 28.42 vs. REGN: 55.36 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
REGN' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 32.37  Med: 89.86 Max: 1910.91
Current: 55.36
32.37
1910.91
Price-to-Operating-Cash-Flow 40.06
REGN's Price-to-Operating-Cash-Flow is ranked lower than
60% of the 179 Companies
in the Global Biotechnology industry.

( Industry Median: 25.11 vs. REGN: 40.06 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
REGN' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 21.64  Med: 49.75 Max: 559.41
Current: 40.06
21.64
559.41
EV-to-EBIT 29.06
REGN's EV-to-EBIT is ranked lower than
66% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. REGN: 29.06 )
Ranked among companies with meaningful EV-to-EBIT only.
REGN' s EV-to-EBIT Range Over the Past 10 Years
Min: -108.7  Med: -5.3 Max: 1948.5
Current: 29.06
-108.7
1948.5
EV-to-EBITDA 27.00
REGN's EV-to-EBITDA is ranked lower than
68% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. REGN: 27.00 )
Ranked among companies with meaningful EV-to-EBITDA only.
REGN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -141.9  Med: -5.9 Max: 387.4
Current: 27
-141.9
387.4
Shiller PE Ratio 178.39
REGN's Shiller PE Ratio is ranked lower than
91% of the 67 Companies
in the Global Biotechnology industry.

( Industry Median: 44.06 vs. REGN: 178.39 )
Ranked among companies with meaningful Shiller PE Ratio only.
REGN' s Shiller PE Ratio Range Over the Past 10 Years
Min: 166.72  Med: 407.54 Max: 4161.1
Current: 178.39
166.72
4161.1
Current Ratio 3.75
REGN's Current Ratio is ranked lower than
63% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. REGN: 3.75 )
Ranked among companies with meaningful Current Ratio only.
REGN' s Current Ratio Range Over the Past 10 Years
Min: 2.17  Med: 6.43 Max: 55.65
Current: 3.75
2.17
55.65
Quick Ratio 3.21
REGN's Quick Ratio is ranked lower than
64% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. REGN: 3.21 )
Ranked among companies with meaningful Quick Ratio only.
REGN' s Quick Ratio Range Over the Past 10 Years
Min: 2.17  Med: 6.32 Max: 55.65
Current: 3.21
2.17
55.65
Days Inventory 496.68
REGN's Days Inventory is ranked lower than
94% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 131.43 vs. REGN: 496.68 )
Ranked among companies with meaningful Days Inventory only.
REGN' s Days Inventory Range Over the Past 10 Years
Min: 97.79  Med: 170.76 Max: 780.78
Current: 496.68
97.79
780.78
Days Sales Outstanding 99.01
REGN's Days Sales Outstanding is ranked lower than
80% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. REGN: 99.01 )
Ranked among companies with meaningful Days Sales Outstanding only.
REGN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 23.13  Med: 93.08 Max: 157.07
Current: 99.01
23.13
157.07
Days Payable 180.56
REGN's Days Payable is ranked higher than
82% of the 424 Companies
in the Global Biotechnology industry.

( Industry Median: 54.11 vs. REGN: 180.56 )
Ranked among companies with meaningful Days Payable only.
REGN' s Days Payable Range Over the Past 10 Years
Min: 131.02  Med: 172.72 Max: 2718.58
Current: 180.56
131.02
2718.58

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.10
REGN's 3-Year Average Share Buyback Ratio is ranked higher than
85% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. REGN: -2.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
REGN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -17.9  Med: -7.25 Max: -2.1
Current: -2.1
-17.9
-2.1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 39.32
REGN's Price-to-Net-Current-Asset-Value is ranked lower than
97% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. REGN: 39.32 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
REGN' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.61  Med: 8.38 Max: 157.38
Current: 39.32
1.61
157.38
Price-to-Tangible-Book 9.08
REGN's Price-to-Tangible-Book is ranked lower than
78% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. REGN: 9.08 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
REGN' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.84  Med: 4.52 Max: 22
Current: 9.08
0.84
22
Price-to-Intrinsic-Value-Projected-FCF 5.19
REGN's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
67% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 3.53 vs. REGN: 5.19 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
REGN' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 4.44  Med: 15.52 Max: 206.31
Current: 5.19
4.44
206.31
Price-to-Median-PS-Value 0.84
REGN's Price-to-Median-PS-Value is ranked higher than
55% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. REGN: 0.84 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
REGN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.18  Med: 0.99 Max: 4.33
Current: 0.84
0.18
4.33
Price-to-Peter-Lynch-Fair-Value 1.88
REGN's Price-to-Peter-Lynch-Fair-Value is ranked lower than
99.99% of the 76 Companies
in the Global Biotechnology industry.

( Industry Median: 1.95 vs. REGN: 1.88 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
REGN' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.87  Med: 2.05 Max: 2.58
Current: 1.88
0.87
2.58
Price-to-Graham-Number 4.35
REGN's Price-to-Graham-Number is ranked lower than
76% of the 188 Companies
in the Global Biotechnology industry.

( Industry Median: 2.84 vs. REGN: 4.35 )
Ranked among companies with meaningful Price-to-Graham-Number only.
REGN' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.33  Med: 5.5 Max: 10.19
Current: 4.35
1.33
10.19
Earnings Yield (Greenblatt) % 3.44
REGN's Earnings Yield (Greenblatt) % is ranked higher than
82% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. REGN: 3.44 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
REGN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -19  Med: -0.9 Max: 17.6
Current: 3.44
-19
17.6
Forward Rate of Return (Yacktman) % 53.62
REGN's Forward Rate of Return (Yacktman) % is ranked lower than
99.99% of the 129 Companies
in the Global Biotechnology industry.

( Industry Median: 14.33 vs. REGN: 53.62 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
REGN' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -8  Med: -1.7 Max: 53.6
Current: 53.62
-8
53.6

More Statistics

Revenue (TTM) (Mil) $5,236.06
EPS (TTM) $ 9.96
Beta1.72
Short Percentage of Float3.19%
52-Week Range $325.35 - 543.55
Shares Outstanding (Mil)107.15

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 5,692 6,213 6,948
EPS ($) 14.64 16.97 20.29
EPS without NRI ($) 14.64 16.97 20.29
EPS Growth Rate
(Future 3Y To 5Y Estimate)
17.66%
Dividends per Share ($)
» More Articles for REGN

Headlines

Articles On GuruFocus.com
Vanguard Sells Medtronic, Cigna in 2nd Quarter Aug 17 2017 
Regeneron to Discontinue Development of Suptavumab for Respiratory Syncytial Virus Aug 14 2017 
Options Trades for Allergan, 3D Systems, Regeneron Pharmaceuticals, Tesla Motors and Yelp include tr Aug 03 2017 
Accessing the Regeneron Second Quarter 2017 Financial and Operating Results Webcast Aug 03 2017 
Regeneron and Sanofi Receive Positive CHMP Opinion for Dupixent® (dupilumab) to Treat Adult Patient Jul 21 2017 
The Best- and Worst-Performing Stocks of Last Decade Jul 16 2017 
Regeneron to Report Second Quarter 2017 Financial and Operating Results and Host Conference Call and Jul 13 2017 
Regeneron Announces the 2017 Winners of the Regeneron Prize for Creative Innovation Jul 13 2017 
Spiros Segalas Gains 5 New Holdings in 2nd Quarter Jul 10 2017 
Regeneron Details Royalty Agreement with Novartis for Canakinumab (ACZ885) Jun 22 2017 

More From Other Websites
Pfizer's (PFE) Besponsa Gets FDA Nod with a Boxed Warning Aug 18 2017
Is Regeneron Pharmaceuticals the Best Biotech Stock to Buy? Aug 17 2017
Seattle Genetics' Adcetris Granted Priority Review by FDA Aug 17 2017
Novo Nordisk's Semaglutide Shows Remarkable Results in Study Aug 17 2017
Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst Aug 17 2017
See what the IHS Markit Score report has to say about Regeneron Pharmaceuticals Inc. Aug 17 2017
Regeneron's (REGN) RSV Drug Suptavumab Fails NURSERY Trial Aug 16 2017
Spectrum (SPPI) Initiates Phase II Study for Cancer Drug Aug 16 2017
Biogen: Goldman Has Conviction! Aug 16 2017
Biotech Stock Roundup: Regeneron Drops RSV Antibody, Gilead HIV Drug Gets Priority Review Aug 16 2017
Regeneron Pharmaceuticals, Inc. – Value Analysis (NASDAQ:REGN) : August 15, 2017 Aug 15 2017
3 Stocks That Could Make You Rich Aug 15 2017
What Amgen’s Analysts Recommend in August 2017 Aug 14 2017
Regeneron to abandon drug for common respiratory virus Aug 14 2017
Regeneron vs. Alexion: Which Stock is a Better Pick Post Q2 Earnings? Aug 14 2017
Regeneron to Discontinue Development of Suptavumab for Respiratory Syncytial Virus Aug 14 2017
Edited Transcript of REGN earnings conference call or presentation 3-Aug-17 12:30pm GMT Aug 12 2017
Forget Teva (TEVA), Buy These 4 Drug Stocks Instead Aug 11 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}